The latest market price and purchasing advice of Mobocertinib

Mobocertinib is an oral small molecule targeted drug, mainly used to treat patients with non-small cell lung cancer (NSCLC) with positive insertion mutations in exon 20 of EGFR. The drug blocks tumor growth signaling pathways by selectively inhibiting mutant EGFR, thereby delaying tumor progression. Mobosetinib has been launched in China, but it has not yet been included in the medical insurance system. Patients still have certain difficulties in purchasing it directly in China. They need to consult the supply situation of local hospital pharmacies in advance.

Due to its recent launch, the supply of mobosetinib in domestic pharmacies or hospital pharmacies is limited, and some areas may need to apply through special hospital channels or wait for supply. If patients urgently need to use this drug, they should contact a professional doctor in advance to confirm the availability of the drug, and reasonably arrange the treatment cycle based on the clinical plan to avoid affecting the efficacy.

In overseas markets, mobosetinib is divided into two types: original drugs and generic drugs. The original drugs include the Hong Kong version and the Japanese Takeda version. The price per box is about 7,000 to 8,000 yuan, which is relatively high. In comparison, the price of generic drugs is more affordable. For example, the generic drug of moboxetinib in the Laos market costs about 3,000 yuan per box, which is only about half of the original drug. The ingredients of generic drugs are basically the same as those of original drugs, which can significantly reduce the financial burden on patients while ensuring the efficacy.

Taking into consideration the price and accessibility at home and abroad, when patients cannot successfully obtain mobosetinib at home, they may consider purchasing generic drugs through regular overseas channels to ensure continuous medication. Regardless of whether you choose original drugs or generic drugs, they should be used under the guidance of professional doctors, and blood routine and liver and kidney functions should be monitored regularly, and attention should be paid to drug efficacy and adverse reactions. At the same time, patients are advised to pay attention to domestic drug approval and medical insurance policy developments. Once moboxetinib is included in medical insurance, it can further reduce financial pressure.

Reference link:https://www.drugs.com